Atomically Engineered Nanozymes for Immunotherapy and Disease Treatment
en-GBde-DEes-ESfr-FR

Atomically Engineered Nanozymes for Immunotherapy and Disease Treatment

03.02.2026 TranSpread

Published in the KeAi journal Nano Biomedicine and Engineering, a new review (DOI: 10.1016/j.nbe.2025.100003) by researchers from Hainan Medical University details how atomically engineed nanozymes (AENs)are engineered to mimic natural enzymes while outperforming them in biomedical applications. These nanostructures can precisely regulate reactive oxygen species (ROS), activate immune pathways, and remodel the tumor microenvironment—killing tumors by immunotherapy.

“From radioimmunotherapy and cuproptosis to ferroptosis and pyroptosis, AENs are being harnessed to induce immunogenic cell death, activate STING pathways, and boost checkpoint blockade therapies,” shares senior author Pir Muhammad. “They also show promise in antibacterial applications, wound healing, and mitigating drug-induced organ toxicity.”

In particular, AENs’ atomic tunability allows the design of targeted, efficient, and personalized therapeutic platforms for more effective treatments of different disease, including rheumatoid arthritis, acute pancreatitis, sepsis, Parkinson's disease , ischemic strokes, pneumonia, and Alzheimer's disease.

Nonetheless, the authors note that while AENs show promise, challenges remain in scaling synthesis, long-term biocompatibility, and precise control of catalytic activity in dynamic biological environments. Future efforts are likely to focus on intelligent nanozyme design, real-time immune monitoring, and clinical translation.

###

References

DOI

10.1016/j.nbe.2025.100003

Original Source URL

https://doi.org/10.1016/j.nbe.2025.100003

About Nano Biomedicine and Engineering

Nano Biomedicine and Engineering (Nano Biomed. Eng.) is an open access, peer-reviewed journal. The aim of Nano Biomed. Eng. is to serve the multidisciplinary community of nano biomedical engineering. The journal presents basic, clinical, and engineering research articles, reviews, highlights, conference proceedings, editorials and short communications in the interdisciplinary field of nanotechnology, biology, medicine and engineering, as well as strategies for disease prevention, diagnosis, treatment, and assessment.

Paper title: Atomically engineered nanozymes (AEN): Revolutionizing catalytic immunemodulation for biomedical advances
Angehängte Dokumente
  • Schematic illustration of recent advances in diagnostic and therapeutic systems based on AENs, including applications in tumor therapy, anti oxidant therapy, anti bacterial therapy
03.02.2026 TranSpread
Regions: North America, United States, Asia, China
Keywords: Applied science, Engineering, Nanotechnology, Technology, Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Referenzen

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Wir arbeiten eng zusammen mit...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement